Lantheus Holdings (STU:0L8) Beneish M-Score: -2.33 (As of Jun. 29, 2026)


STU:0L8 Lantheus Holdings Inc STU:0L8
87 GF Score
Price €96.50
GF Value €79.89
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lantheus Holdings Beneish M-Score?

Lantheus Holdings STU:0L8 +1.37% 87 Beneish M-Score is -2.33 as of Jun. 29, 2026. GuruFocus rates STU:0L8 with a GF Score™ of 87/100 and a GF Value™ of €79.89 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 908 Drug Manufacturers companies, Lantheus Holdings ranks worse than 62.44% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.33 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Lantheus Holdings's Beneish M-Score or its related term are showing as below:

STU:0L8' s Beneish M-Score Range Over the Past 10 Years
Min: -3.6   Med: -2.74   Max: -1.07
Current: -2.33

During the past 13 years, the highest Beneish M-Score of Lantheus Holdings was -1.07. The lowest was -3.60. And the median was -2.74.


Lantheus Holdings Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Lantheus Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lantheus Holdings Beneish M-Score Chart

Lantheus Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.88 -2.75 -2.22 -2.88 -2.17

Lantheus Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.86 -2.84 -2.39 -2.17 -2.33

STU:0L8 vs LQDA, HIMS, AMRX: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's Beneish M-Score falls into.


STU:0L8
87GF Score
Lantheus Holdings Inc STU:0L8
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lantheus Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Lantheus Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0275+0.528 * 1.0585+0.404 * 2.423+0.892 * 0.932+0.115 * 0.7764
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2218+4.679 * -0.090203-0.327 * 0.9739
=-2.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €309 Mil.
Revenue was 326.393 + 347.395 + 327.18 + 327.765 = €1,329 Mil.
Gross Profit was 199.748 + 205.707 + 189.456 + 208.957 = €804 Mil.
Total Current Assets was €815 Mil.
Total Assets was €2,030 Mil.
Property, Plant and Equipment(Net PPE) was €136 Mil.
Depreciation, Depletion and Amortization(DDA) was €68 Mil.
Selling, General, & Admin. Expense(SGA) was €399 Mil.
Total Current Liabilities was €288 Mil.
Long-Term Debt & Capital Lease Obligation was €541 Mil.
Net Income was 102.431 + 46.191 + 23.661 + 68.281 = €241 Mil.
Non Operating Income was 64.853 + -4.111 + 0.079 + 12.359 = €73 Mil.
Cash Flow from Operations was 108.235 + 77.012 + 89.71 + 75.521 = €350 Mil.
Total Receivables was €323 Mil.
Revenue was 344.807 + 373.51 + 341.239 + 366.111 = €1,426 Mil.
Gross Profit was 219.872 + 237.36 + 218.156 + 237.614 = €913 Mil.
Total Current Assets was €1,317 Mil.
Total Assets was €1,901 Mil.
Property, Plant and Equipment(Net PPE) was €167 Mil.
Depreciation, Depletion and Amortization(DDA) was €58 Mil.
Selling, General, & Admin. Expense(SGA) was €351 Mil.
Total Current Liabilities was €229 Mil.
Long-Term Debt & Capital Lease Obligation was €568 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(308.937 / 1328.733) / (322.593 / 1425.667)
=0.232505 / 0.226275
=1.0275

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(913.002 / 1425.667) / (803.868 / 1328.733)
=0.640403 / 0.604988
=1.0585

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (815.079 + 136.292) / 2029.798) / (1 - (1316.996 + 167.224) / 1901.082)
=0.531298 / 0.219276
=2.423

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1328.733 / 1425.667
=0.932

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(58.263 / (58.263 + 167.224)) / (67.979 / (67.979 + 136.292))
=0.258387 / 0.332788
=0.7764

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(399.212 / 1328.733) / (350.587 / 1425.667)
=0.300446 / 0.245911
=1.2218

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((540.581 + 288.189) / 2029.798) / ((567.632 + 229.402) / 1901.082)
=0.408302 / 0.419253
=0.9739

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(240.564 - 73.18 - 350.478) / 2029.798
=-0.090203

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Lantheus Holdings has a M-score of -2.39 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.33 mean?
Lantheus Holdings (STU:0L8) has a Beneish M-Score of -2.33 as of Jun. 29, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lantheus Holdings and its competitors. According to the industry distribution chart, Lantheus Holdings ranks #567 out of 908 companies in the Drug Manufacturers industry, placing it in the top 62.4%.
Is Lantheus Holdings' Beneish M-Score too high?
Lantheus Holdings' current Beneish M-Score is -2.33. Based on the distribution chart, Lantheus Holdings ranks #567 out of 908 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lantheus Holdings has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Beneish M-Score compare to LQDA and HIMS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #567 out of 908 companies for Beneish M-Score. This places Lantheus Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lantheus Holdings and its competitors. Lantheus Holdings's current Beneish M-Score is -2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (STU:0L8) is currently considered Modestly Overvalued. The stock's GF Value™ is €79.89, compared to a current price of €96.50 — trading 20.8% above its estimated fair value. The current Beneish M-Score is -2.33. Lantheus Holdings' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Lantheus Holdings (STU:0L8), the current Beneish M-Score is -2.33 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lantheus Holdings (STU:0L8) Overvalued in 2026?

Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued. The current stock price of €96.50 is trading 20.8% above its estimated GF Value™ of €79.89. GuruFocus considers Lantheus Holdings to be Modestly Overvalued.

Key valuation signals for STU:0L8:

  • Beneish M-Score: -2.33
  • GF Value™: €79.89 vs. price of €96.50 (20.8% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the STU:0L8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lantheus Holdings Business Description

Other Exchanges LNTH:USA1LNTH:Italy
Address 201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
87GF Score

Get the complete analysis for STU:0L8

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€96.50
Price
€79.89
GF Value